About MARAbio
MARAbio is a company based in Salt Lake City (United States) founded in 2016 by Judy Van De Water and Michael S Paul. MARAbio has raised $19.06 million across 1 funding round from investors including MAK Capital. MARAbio offers products and services including MARA Blood Test. MARAbio operates in a competitive market with competitors including Lineagen, Linus Biotechnology, Pediatric Bioscience, SensOmics and NeuroPoint Dx, among others.
- Headquarter Salt Lake City, United States
- Founders Judy Van De Water, Michael S Paul
- SectorsHealthcare
- Email••••••••
- Website marabio.com
- Social LinkedIn Facebook Instagram
- Total Equity Funding$19.06M (USD)
in 1 rounds
- Latest Funding Round$19.06M (USD), Series A
Sep 2024
- Investors
Products & Services of MARAbio
MARAbio offers a comprehensive portfolio of products and services, including MARA Blood Test.
Blood test to detect antibodies predicting autism risk in children.
Funding Insights of MARAbio
MARAbio has successfully raised a total of $19.06M through 1 strategic funding round. The most recent funding activity was a Series A round of $19.06 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19.06M
- Total Rounds 1
- Last Round Series A — $19.06M
- First Round $19.06M
(Sep 2024)
- Investors Count 1
All 1 funding rounds of MARAbio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $19.06M | Series A | – | MAK Capital | – |
1 investors in total: 1 institutional.
Investors in MARAbio
MARAbio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include MAK Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | makcapitalfund.com | - |
Investor details for MARAbio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MARAbio
2 people are tracked at MARAbio (2 in leadership).
| Name | Role | Group |
|---|---|---|
Judy Van De Water | Co-Founder | Leadership |
Michael S Paul | Co-Founder & CEO | Leadership |
Complete people profiles for MARAbio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MARAbio
2 dated milestones of MARAbio across 8 years, from founding to its latest funding, stage changes and deals.
- Founded MARAbio is founded.
- Funding First funding round of $19.1M.
Competitors of MARAbio
MARAbio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lineagen, Linus Biotechnology, Pediatric Bioscience, SensOmics and NeuroPoint Dx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lineagen.com | 2002 | Salt Lake, United States | $66.93M | 40 | Sequencing-based diagnostic tests and services for autism are provided. | |
| linusbio.com | 2020 | New York, United States | $47.65M | – | Developer of diagnostic tests for central nervous system and gastrointestinal disorders | |
| pediatricbioscience.com | 2006 | Sacramento, United States | $2.44M | – | Provides blood biomarker-based diagnostics for autism spectrum disorders. | |
| sensomics.com | 2007 | Toronto, Canada | – | – | Precision medicine for children's health is provided through genomic integration. | |
| neuropointdx.com | 2006 | Madison, United States | – | – | Metabolomics for neuro-developmental disorders | |
| fbbbio.com | 2020 | Coralville, United States | $401,000 | – | In-vitro diagnostic tests for COVID-19 and neurological diseases are developed. | |
| autism-biotech.com | 2011 | Belfast, United Kingdom | $51,300 | – | Develops biochemical tests for early autism diagnosis. | |
| metabolus.com | 2015 | San Diego, United States | – | 33 | Develops diagnostics for neurodegenerative and neuropsychiatric disorders. | |
| neuraclegen.com | 2018 | Seoul, South Korea | – | – | Develops gene therapies using adeno-associated virus technology to treat various diseases. |
Detailed competitors of MARAbio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MARAbio
The website of MARAbio (marabio.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▲ 255.5% vs previous month
Latest news on Marabio
Complete news archive for MARAbio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to MARAbio
10 companies that operate in the same segment as MARAbio (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MARAbio
MARAbio was founded in 2016 and raised its 1st funding round 8 years after it was founded.
MARAbio is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Michael S Paul is the current CEO of MARAbio. They have also founded this company.
MARAbio is a funded company, having raised a total of $19.06M across 1 funding round to date. The company's 1st funding round was a Series A of $19.06M, raised on Sep 2024.
MARAbio was founded in 2016 in Salt Lake City, United States, within the biotechnology sector focused on diagnostic tools. Precision blood tests are developed to identify specific autoantibodies in women, which are linked to autism development in children. Operations center on early risk assessment through this technology, supporting maternal health evaluations in clinical settings across the U.S.
MARAbio's top competitors include Linus Biotechnology, Lineagen and FBB Biomed.
MARAbio offers MARA Blood Test.
MARAbio has 1 investor. Key investors include MAK Capital.